Objective To evaluate the clinical effect and safety of high intensity focused ultrasotmd(HIFU) for treating the uterine leiomyomata. Methods The patients with uterine leiomyornata who had born children were chosen as the eandidates, The high intensity focused ultrasound tumor therapeutic system was applied to focus the extraeorporeal ultrasound inside the uterine lieomyomata. The real-time two-dimensional ultrasonography was used to guide the location of the focal field and monitor the ablating procedure. The uterus ultrasonography, myomx related signs,syrnptoms were performed for follow-up before and after HIFU treatment. Results Among 65 eases who accepted the HIFU ablation,95% of them showed short-term or long-term effect. 5 % of them showed no effect. Conclusion HIFU is a safe and effective method for the treatment of uterine leiomyomata.

Objective To evaluate the efficacy and safety of a new ultrafiltration device for treating refractory heart failure patients.Methods A total of 52 patients (37 male,age 29-85 (33 ± 44) years)with refractory heart failure were treated using a new ultrafiltration device (FQ-16).Body weight,dyspnea score,oxygen saturation (SatO2),left ventricular ejection fraction (LVEF),BUN,creatinine,electrolytes and blood gas analysis were assessed before and after the treatment.Hypotension event and other main adverse events were recorded.Results Ultrafiltration duration ranged between 8-22 hours.Total ultrafiltration volume was (4 489 ± 1 548) ml.Compared with baseline,patients' body weight decreased from (75.3 ± 8.74) kg to (69.8 ± 8.39) kg (P ＜ 0.01),dyspnea score improved from 2.47 ± 1.55 to 12.87±3.61 (P＜0.01) and SatO2 increased from 91.0 ±6.01 to 96.4 ±2.52 (P ＜0.01) and LVEF increased from (30.0 ± 4.1) ％ to (36.0 ± 4.3) ％ (P ＜ 0.01) after ultrafiltration.Blood creatinine,BUN,electrolytes and blood gas analysis values were similar at baseline and post ultrafiltration.No hypotension event and other main adverse events occurred during the ultrafiltration treatment.Conclusions The novel ultrafiltration device adequately relieved hypervolemia and dyspnea in patients with refractory heart failure and the treatment process is safe in this patient cohort.